Sy-Shi Wang
Plus aucun poste en cours
Profil
Sy-Shi Wang worked as an Executive Director of Clinical Operations at Acucela, Inc. and Ergomed Plc, as a Staff Scientist at Geron Corp., and as a Senior Manager of Clinical Operations at CTI BioPharma Corp.
She also served as a Vice President of Clinical Development at Light Sciences Oncology, Inc. Wang holds a doctorate degree from the University of Medicine & Dentistry of New Jersey and an undergraduate degree from National Taiwan University.
Anciens postes connus de Sy-Shi Wang
| Sociétés | Poste | Fin |
|---|---|---|
| ERGOMED | Directeur Technique/Scientifique/R&D | - |
| ACUCELA INC | Directeur Technique/Scientifique/R&D | - |
| CTI BIOPHARMA CORP. | Corporate Officer/Principal | - |
| GERON CORPORATION | Corporate Officer/Principal | - |
Light Sciences Oncology, Inc.
 Light Sciences Oncology, Inc. Pharmaceuticals: MajorHealth Technology Light Sciences Oncology, Inc. operates as a pharmaceutical company. It develops Aptocine for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia. The company was founded in 1994 and is headquartered in Bellevue, WA. | Corporate Officer/Principal | - |
Formation de Sy-Shi Wang
| National Taiwan University | Undergraduate Degree |
| University of Medicine & Dentistry of New Jersey | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GERON CORPORATION | Health Technology |
| ERGOMED | Commercial Services |
| Entreprise privées | 3 |
|---|---|
Light Sciences Oncology, Inc.
Light Sciences Oncology, Inc. Pharmaceuticals: MajorHealth Technology Light Sciences Oncology, Inc. operates as a pharmaceutical company. It develops Aptocine for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia. The company was founded in 1994 and is headquartered in Bellevue, WA. | Health Technology |
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
Acucela, Inc.
 Acucela, Inc. Pharmaceuticals: MajorHealth Technology Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA. | Health Technology |